2024
(333) TRENDS IN PHOSPHODIESTERASE TYPE 5 INHIBITOR PRESCRIPTIONS AND COST: MEDICARE ANALYSIS 2017-2021
Cahill E, Reddy S, Rotker K, Honig S. (333) TRENDS IN PHOSPHODIESTERASE TYPE 5 INHIBITOR PRESCRIPTIONS AND COST: MEDICARE ANALYSIS 2017-2021. The Journal Of Sexual Medicine 2024, 21: qdae167.321. DOI: 10.1093/jsxmed/qdae167.321.Peer-Reviewed Original ResearchPhosphodiesterase type 5Non-urologistsPDE5 inhibitorsPhosphodiesterase type 5 inhibitorsMedicare Part D databaseMedicare Part D Public Use FilesCompared urologistsPrescribed tadalafilPrescribed sildenafilSildenafil prescriptionsCost of medicationsErectile dysfunctionInhibitor medicationPrescribing patternsUrologistsPatient comfortPrimary care providersSildenafilTadalafilType 5
2001
Lecture 3
Berger R, Billups K, Brock G, Broderick G, Dhabuwala C, Goldstein I, Hakim L, Hellstrom W, Honig S, Levine L, Lue T, Munarriz R, Montague D, Mulcahy J, Nehra A, Rogers Z, Rosen R, Seftel A, Shabsigh R, Steers W. Lecture 3. International Journal Of Impotence Research 2001, 13: s39-s43. PMID: 11781746, DOI: 10.1038/sj.ijir.3900777.Peer-Reviewed Original ResearchConceptsPrimary care providersClinical characteristics of painHealth care professionalsCharacteristics of painAssociated psychosocial consequencesModified Delphi methodPeer-reviewed literatureCare providersClinical characteristicsCare professionalsErectile dysfunctionPathophysiological characteristicsPsychosocial consequencesAbsence of painAmerican Foundation for Urologic DiseaseMedical careMultidisciplinary panelClassification of priapismDiagnosis of priapismMulti-institutional trialsMedical conditionsTreatment of priapismClosed compartment syndromeConsequences of delayed treatmentGuidelines Committee